Antimycotic therapy: from prophylaxis to treatment
Authors:
J. Haber 1; Z. Ráčil 2
Authors‘ workplace:
I. interní klinika – klinika hematologie, VFN a 1. LF UK Praha
1; Interní hematologická a onkologická klinika, LM MU a FN Brno
2
Published in:
Transfuze Hematol. dnes,19, 2013, No. 1, p. 39-43.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Guidelines for the management of patients with invasive fungal infections have recently been defined. In a short overview, the role of systemic antifungals in prophylaxis and therapy of invasive candidiasis and aspergillosis are reviewed.
Key words:
invasive fungal infection, candidiasis, aspergillosis, prophylaxis, therapy, guidelines
Sources
1. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001; 32: 851-854.
2. O‘Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ. Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Program 2003; 438-472.
3. de Pauw BE, Rubin RH. Empiric versus preemptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy. Transpl Infect Dis 2006; 8: 1-2.
4. Ruping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs 2008; 68: 1941-1962.
5. Ráčil Z, Haber J, Drgoňa Ľ, et al. Primární profylaxe invazivních mykotických infekcí u hematoonkologických nemocných – doporučení odborníků. Postgraduální medicína 2009; 11(Mimořádná příloha): 39-42.
6. Haber J, Forsterová K. Primární antimykotická profylaxe u nemocných po autologní transplantaci kostní dřeně: ano či ne? Postgraduální medicína 2009; 11(Mimořádná příloha): 10-15.
7. Žák P, Zavřelová A. Primární antimykotická profylaxe invazívní mykotické infekce u nemocných s hematologickou malignitou: NHL, HL, B-CLL, HCL, AA. Postgraduální medicína 2009; 11(Mimořádná příloha): 22-24.
8. Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95: 1762-1768.
9. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
10. Herbrecht R, Fluckiger U, Gachot B, et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Suppls 2007; 5: 49-59.
11. Herbrecht R, Flückiger U, Gachot B, et al. 2011 update ECIL-4 antifungal therapy in leukemia patients. At the 4th European Conference on Infections in Leukemia. 6 Sept 2011.
12. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
13. Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50: 1559-1567.
14. Salmeron G, Porcher R, Bergeron A, et al. Persistent poor long-term prognosis of allogeneic hematopoietic stem cell transplant recipients surviving invasive aspergillosis. Haematologica 2012; 97: 1357-1363.
15. Ráčil Z, Haber J, Drgoňa Ľ, et al. Empirická antimykotická léčba febrilní neutropenie u nemocných s hematologickou malignitou – doporučení odborníků – s podporou CELL, ČHS JEP, ČOS JEP, SCHS SLS. Postgraduální medicína 2010; 12(Mimořádná příloha): 66-68.
16. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48: 1042-1051.
17. Pagano L, Caira M, Nosari A, et al. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica 2011; 96: 1366-1370.
18. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: 427-431.
19. Aguilar-Guisado M, Martin-Pena A, Espigado I, et al. Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach. Haematologica 2012; 97: 464-471.
20. Maertens J, Huysmans G, Theunissen K. Early diagnosis and preemptive therapy of pulmonary mold infections in high-risk patients. Curr Infect Dis Rep 2008; 10: 459-465.
21. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-1250.
22. Haber J, Ráčil Z, Drgoňa Ľ. Preemptivní antimykotická léčba febrilní neutropenie u nemocných s hematologickou malignitou – změna dosavadní strategie léčby invazivních mykotických onemocnění? Postgraduální medicína 2010; 12(Suppl 5): 9-15.
23. Haber J, Mallátová N. Léčba invazivních mykotických onemocnění – novinky roku 2011. Farmakoterapie 2012; 8: 353-359.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2013 Issue 1
Most read in this issue
- High-risk monoclonal gammopathy of undetermined significance – to treat or not to treat?
- Cryopreservation of blood – history, methods and the current status
- Antimycotic therapy: from prophylaxis to treatment
- Clinical aspects of „true“ non-secretory multiple myeloma